Arsenal Capital Management

InterShunt designs and develops a catheter-based minimally-invasive procedure to provide relief for millions suffering from heart failure. It believes that left atrial decompression holds the key to reducing symptoms for those who suffer. It also believes that they can do this using a simple catheter procedure. Most importantly, they believe they can do this without the use of an implant. It was founded in 2015 and is headquartered in St Louis, Missouri.

Kypha Inc. is a life sciences company focused on developing and commercializing in-vitro diagnostic biomarker tests for inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Kypha aims to provide rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. With a core team supported by scientific advisors and clinical collaborators, Kypha has successfully secured federal grants and raised private capital to advance its diagnostic products toward regulatory approval and market launch. The company's technology is designed for scalability, facilitating testing in diverse settings from home health to clinical laboratories, ultimately improving patient outcomes through timely intervention.

Kypha Inc. is a life sciences company focused on developing and commercializing in-vitro diagnostic biomarker tests for inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Kypha aims to provide rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. With a core team supported by scientific advisors and clinical collaborators, Kypha has successfully secured federal grants and raised private capital to advance its diagnostic products toward regulatory approval and market launch. The company's technology is designed for scalability, facilitating testing in diverse settings from home health to clinical laboratories, ultimately improving patient outcomes through timely intervention.

Bonfyre Inc. is an employee engagement platform founded in 2013 and based in Saint Louis, Missouri. The company focuses on transforming workplace culture by providing technology that enhances employee recognition, communication, feedback, and event management. Its mobile-first platform offers real-time communication tools such as announcements, targeted broadcasts, and pop surveys, which help organizations foster camaraderie, align their culture, and gather valuable HR insights. By modernizing employee communications, Bonfyre enables companies to build stronger relationships and increase engagement, ultimately promoting a collaborative and innovative work environment.

Bonfyre Inc. is an employee engagement platform founded in 2013 and based in Saint Louis, Missouri. The company focuses on transforming workplace culture by providing technology that enhances employee recognition, communication, feedback, and event management. Its mobile-first platform offers real-time communication tools such as announcements, targeted broadcasts, and pop surveys, which help organizations foster camaraderie, align their culture, and gather valuable HR insights. By modernizing employee communications, Bonfyre enables companies to build stronger relationships and increase engagement, ultimately promoting a collaborative and innovative work environment.

Kypha Inc. is a life sciences company focused on developing and commercializing in-vitro diagnostic biomarker tests for inflammation and autoimmune disorders. Based in St. Louis, Missouri, the company offers the COMP ACT System, which enhances the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. Kypha aims to provide rapid and accurate assessments of inflammation levels, enabling healthcare professionals to make timely and informed clinical decisions. With a core team supported by scientific advisors and clinical collaborators, Kypha has successfully secured federal grants and raised private capital to advance its diagnostic products toward regulatory approval and market launch. The company's technology is designed for scalability, facilitating testing in diverse settings from home health to clinical laboratories, ultimately improving patient outcomes through timely intervention.